[Bleeding risk in ST-segment elevation myocardial infarction].
Coronary reperfusion of acute coronary syndromes with ST segment elevation requires medical treatment involving potential thrombolysis as well as very potent anticoagulant and antiplatelet medications. In such a therapeutic setting, the risk of bleeding complications may be high and should be taken into account accordingly. An accurate definition of these bleeding complications is crucial in order to compare all currently available treatments and strategies appropriately. The heterogeneous definitions often published in the literature make any valid interpretations of the results very difficult. These bleeding complications, which affect negatively the outcome of patients undergoing treatment should be adequately anticipated in our treatment strategies. An exhaustive knowledge of the bleeding risk factors is necessary in order to adjust the treatment modalities. The occurrence of bleeding may be related to the vascular approach used for cardiac catheterization. In this respect, the superiority of the radial approach has been widely demonstrated. In addition, certain instances of bleeding are not related to the vascular approach, such as digestive and neurological bleeding which can have very severe consequences. Consequently, it is necessary to adapt treatments with heterogeneous potential for bleeding to individual bleeding risk factors, which may be quantified by scores measuring the bleeding risk. Finally, treatment combinations must often be carefully tailored to the characteristics of each individual patient.
ICPS, Massy, France. hbenamer@club-internet.fr
H
H
Benamer
B
B
Meftout
B
B
Chevalier
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors
D005343:Fibrinolytic Agents